登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：001255 证券简称：博菲电气 公告编号：2026-016 浙江博菲电气股份有限公司 关于2025年限制性股票激励计划预留授予 限制性股票授予登记完成的公告（新增股份） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1、上市日（新增股份）：2026年2月9日 2、登记数量（新增股份）：67.20万股 3、授予价格：12.98元/股 4、授予登记人数（新增股份）：4人 5、授予的股票来源（新增股份）：公司向激励对象定向发行的本公司人民币A股普通股 （四）2025年5月29日，公司召开第三届董事会第十五次会议、第三届监事会第十二次会议，审议通过 了《关于调整公司2025年限制性股票激励计划相关事项的议案》《关于向公司2025年限制性股票激励计 划激励对象首次授予限制性股票的议案》。公司监事会对激励对象名单进行了核查并发表了意见。 （五）2025年11月28日，公司召开第三届董事会第二十二次会议、第三届监事会第十七次会议，审议通 过了《关于回购注销2025年限制性股票激励计划部分限制性股 ...

Group 1 - The company held its sixth board meeting on July 5, 2024, where it approved adjustments to the stock option incentive plans for 2018, 2019, 2021, and 2022, including changes to exercise prices and the cancellation of certain stock options from the 2019 plan [1][12][24] - The number of initial grant incentive recipients was adjusted from 310 to 298, and the total number of stock options granted was reduced from 15,605,490 to 15,238,124, with the exercise price changed from 13.35 CNY to 13.05 CNY [1][12] - The board recognized that the exercise conditions for the fifth exercise period of the 2019 stock option incentive plan had been met, allowing 298 recipients to exercise their options at the adjusted price [1][12] Group 2 - On December 20, 2024, the company held its sixth board meeting where it approved the cancellation of stock options from the 2019 incentive plan that were unlocked but not exercised [2][14] - The cancellation was due to the failure of incentive recipients to fully exercise their options within the exercise period [2][14] Group 3 - The company held its fifth board meeting on September 30, 2021, where it approved the 2021 stock option incentive plan, which was deemed beneficial for the company's sustainable development [3][20] - The plan included the granting of 52,419,000 stock options to 1,097 recipients, with the initial grant date set for December 3, 2021 [5][21] Group 4 - The company adjusted the exercise price of the 2021 stock option incentive plan from 35.87 CNY to 35.76 CNY on July 6, 2022, due to the implementation of the annual equity distribution plan [5][8] - The board approved the granting of stock options to 365 recipients on September 15, 2022, totaling 13,101,000 options [6][23] Group 5 - On February 21, 2023, the company approved adjustments to the number of stock options granted in the 2021 plan, reducing the total from 52,092,000 to 47,733,260 due to departures and performance issues among recipients [7][9] - The exercise price for the first exercise period was set at 35.76 CNY, with 974 recipients eligible to exercise their options [7][10] Group 6 - The company held its sixth board meeting on October 20, 2023, where it approved further adjustments to the 2021 stock option incentive plan, including a reduction in the number of options from 12,785,800 to 11,482,716 due to similar reasons as previous adjustments [9][10] - The exercise price for the first exercise period was adjusted to 35.63 CNY [10][11] Group 7 - The company held its sixth board meeting on December 29, 2023, where it approved adjustments to the 2021 stock option incentive plan, reducing the number of options from 9,551,800 to 8,824,780 for the second exercise period [11][15] - The exercise price for this period was set at 35.63 CNY [11][15] Group 8 - The company held its sixth board meeting on February 5, 2026, where it approved the cancellation of stock options from the 2021 plan that were unlocked but not exercised [18][28] - The adjustments were made in accordance with the relevant regulations and were deemed to have no substantial impact on the company's financial status [32]

Core Viewpoint - The company has completed the registration capital change and obtained a new business license following the approval of its board and shareholders to reduce registered capital and amend its articles of association [1] Group 1: Company Actions - The company held its 11th board meeting on August 25, 2025, and the first extraordinary shareholders' meeting on September 10, 2025, where it approved the proposal to reduce registered capital and amend the articles of association [1] - The company has completed the necessary procedures for the change of registered capital and the filing of the amended articles of association, receiving a new business license from the Changchun Market Supervision Administration [1] Group 2: Company Information - The new registered capital of the company is 456,828,880 yuan [1] - The company is classified as a listed other joint-stock company, with its legal representative being Wu Jinhua [1] - The company was established on June 26, 1993, and is located at 2888 Nansha Street, Economic Development Zone, Changchun City [1] - The company's business scope includes manufacturing and sales of industrial control systems, mechanical and electrical equipment, smart control system integration, IoT technology services, industrial internet data services, and investment activities [1]

Group 1 - The company, Nanchang Mining Machinery Group Co., Ltd., has approved an investment of $30 million to acquire a 10% stake in Eagle Canyon Gold Limited through its wholly-owned subsidiary, NMS International Holding Pte. Ltd. [1][2][3] - The overall valuation of Eagle Canyon Gold Limited is set at $30 million, with the investment being contingent upon the completion of various preconditions, including internal restructuring and regulatory approvals [2][4][5]. - The investment aims to expand the company's overseas market presence and enhance its competitiveness in the mineral resources sector [15][18][19]. Group 2 - The transaction does not constitute a major asset restructuring or related party transaction, and it requires approval from domestic regulatory authorities for the outbound investment [2][3][17]. - The investment will provide the company with priority cooperation rights for mining projects, thereby injecting new growth momentum into its core business [18][19]. - The company plans to utilize the funds from the investment for restructuring and operational expenses related to the mining projects [5][18]. Group 3 - The investment is part of the company's strategic plan to extend its industrial chain and align with its long-term development strategy [15][18]. - The company has engaged intermediaries to conduct asset evaluations for Eagle Canyon Gold Limited, which are still ongoing [4][5]. - The investment is expected to facilitate the company's transition from traditional equipment sales to broader mining operation services, thus expanding its business ecosystem [18][19].

Core Viewpoint - Zhejiang Aoxiang Pharmaceutical Co., Ltd. has announced that its partner STADA Arzneimittel AG's subsidiary Spirig HealthCare AG has received approval from the Swiss Medicines Agency for the marketing of tofacitinib citrate tablets, marking a significant milestone for the company's international expansion efforts [1][4]. Group 1: Product Information - The product, tofacitinib citrate, is the world's first approved oral Janus kinase inhibitor, used for treating autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [2]. - The commercial name for tofacitinib citrate is Xeljanz, developed by Pfizer, which received FDA approval in November 2012 and entered the Chinese market in March 2017. The global sales forecast for 2024 is approximately $1.168 billion [2]. Group 2: Company Impact - The approval for tofacitinib citrate tablets in Switzerland establishes a solid foundation for the company's business expansion in the Swiss market and is expected to positively influence its ongoing expansion into the European market, enhancing brand recognition and market share [4]. - The collaboration with STADA on this formulation product signifies a breakthrough in the company's integrated strategy of "intermediates + specialty APIs + formulations," enriching its product line and enhancing competitive advantages [4].

证券代码：603056 证券简称：德邦股份 公告编号：2026-024 德邦物流股份有限公司 关于本次终止上市事项 开设现金选择权信息服务的提示性公告 德邦物流股份有限公司 关于第二期员工持股计划出售完毕 暨终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 德邦物流股份有限公司（以下简称"公司"）于2026年1月29日召开2026年第一次临时股东会，审议通过 《关于以股东会决议方式主动终止公司股票上市事项的议案》，公司将以股东会决议方式主动撤回A股 股票在上海证券交易所的上市交易，并申请股票进入全国中小企业股份转让系统退市板块继续交易（以 下简称"本次终止上市"）。公司股票进入现金选择权行权申报阶段。根据本次终止上市相关工作安排， 现金选择权申报时间定为2026年2月9日（星期一）、2月10日（星期二）、2月11日（星期三）、2月12 日（星期四）（连续四个工作日）的9:30-11:30、13:00-15:00；现金选择权申报简称及代码为：德邦现 金，770004。 为更好地保障中小投资者的利益，确保有意愿行使现金选 ...

Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2026 on February 26, 2026, combining on-site voting and online voting [3][4][47] - The meeting will discuss several proposals, including related party transactions, which require abstention from voting by related shareholders [6][7] - The registration date for shareholders to attend the meeting is set for February 10, 2026 [5] Group 2 - The company plans to engage in financial derivatives business to hedge risks associated with international operations, with a maximum trading amount of RMB 1 billion over the next twelve months [20][22] - The financial derivatives will include products such as forwards, options, swaps, and futures, aimed at mitigating currency and interest rate risks [21][22] - The board of directors has approved the proposal to conduct financial derivatives business, which will be submitted for shareholder approval at the upcoming meeting [46][29] Group 3 - The company anticipates a total of RMB 1,196.8 million in related party transactions for 2026, which will be subject to shareholder approval [32][36] - The related party transactions are necessary for the company's daily operations and are expected to be conducted at fair market prices [37][39] - The independent directors have reviewed and approved the related party transaction proposal, confirming it does not harm the interests of the company or its shareholders [38][39]

根据有关法律法规及《深圳证券交易所上市公司自律监管指引第1号一一主板上市公司规范运作》的规 定，遵循规范、安全、高效、透明的原则，公司制定了《募集资金管理办法》，对募集资金的存储、审 批、使用、管理与监督做出了明确的规定，以在制度上保证募集资金的规范使用。 证券代码：002074 证券简称：国轩高科 公告编号：2026-012 国轩高科股份有限公司 前次募集资金使用情况专项报告 根据中国证券监督管理委员会（以下简称"中国证监会"）《监管规则适用指引一一发行类第7号》等法 规规定，国轩高科股份有限公司（以下简称"公司"）将截至2025年9月30日止前次募集资金使用情况报 告如下： 一、前次募集资金情况 （一）实际募集资金金额、资金到位时间 经中国证监会证监许可[2021]1421号《关于核准国轩高科股份有限公司非公开发行股票的批复》核准， 公司向特定对象大众汽车（中国）投资有限公司（以下简称"大众中国"）发行384,163,346股新股，每股 发行价格为人民币19.01元。截至2021年11月5日，公司本次向特定对象发行A股股票的募集资金总额为 人民币7,302,945,207.46元，扣除各项发行费用总计人民 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000712 证券简称：锦龙股份 公告编号：2026-19 广东锦龙发展股份有限公司 关于股东股份被重新第二次司法拍卖的提示性公告 二、风险提示及对公司的影响 1．本次拍卖尚处于公示阶段，后续可能涉及竞拍、流拍、缴款、法院裁定、股权变更过户等环节，最 终拍卖结果尚存在不确定性。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 广东锦龙发展股份有限公司（下称"公司"）今日接到股东朱凤廉女士函告，获悉其所持有的公司部分股 份将被重新第二次司法拍卖。具体情况如下： 一、股东股份被拍卖基本情况 1．本次股份被拍卖基本情况 ■ 注：（1）上述司法拍卖的具体情况请关注京东网司法拍卖网络平台（http://sifa.jd.com）上公示的相关 信息。 （2）上述司法拍卖的股份此前已被广东省东莞市中级人民法院冻结，详见公司于2025年2月25日披露的 《关于股东股份被冻结的公告》（公告编号：2025-17），第一次拍卖的具体情况详见公司于2026年1月 9日披露的《关于股东股份被司法拍卖的进展公告》（公告编号：202 ...

证券代码：600008 证券简称：首创环保 公告编号：2026-005 北京首创生态环保集团股份有限公司 第九届董事会2026年度第一次临时会议 决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 北京首创生态环保集团股份有限公司（以下简称"公司"）第九届董事会2026年度第一次临时会议于2026 年1月30日以电子邮件的方式发出召开董事会会议的通知，会议于2026年2月5日在公司会议室以现场及 通讯表决方式召开。会议应出席董事10人，实际出席董事10人。会议由董事长李伏京主持，部分高管列 席会议。本次会议符合《公司法》和《公司章程》之规定。会议经表决后，全体董事一致通过如下决 议： 一、审议通过《关于注册发行银行间债务融资工具（DFI）的议案》 1．同意公司向中国银行间市场交易商协会申请统一注册债务融资工具（DFI），并在注册批复两年有 效期内择机发行，总规模不超过人民币102亿元（含102亿元），其中，超短期融资券和短期融资券实行 余额管理，滚动发行； 2．如本议案获得股东会批准，公司董事会拟提请股东会授权董事会，并 ...